Literature DB >> 22492501

Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure.

Rachel I Gafni1, Jaime S Brahim, Panagiota Andreopoulou, Nisan Bhattacharyya, Marilyn H Kelly, Beth A Brillante, James C Reynolds, Hua Zhou, David W Dempster, Michael T Collins.   

Abstract

Parathyroid hormone (PTH) has variable actions on bone. Chronically increased PTH is catabolic and leads to osteoporosis; yet intermittent administration is anabolic and increases bone mass. PTH deficiency is associated with decreased bone remodeling and increased bone mass. However, the effects of PTH replacement therapy on bone in hypoparathyroidism are not well known. We discontinued calcitriol therapy and treated 5 hypoparathyroid subjects (2 adults and 3 adolescents) with synthetic human PTH 1-34 (hPTH 1-34), injected two to three times daily for 18 months, with doses individualized to maintain serum calcium at 1.9 to 2.25 mmol/L. Biochemical markers and bone mineral density (BMD) were assessed every 6 months; iliac-crest biopsies were performed before and after 1 year of treatment. hPTH 1-34 therapy significantly increased bone markers to supranormal levels. Histomorphometry revealed that treatment dramatically increased cancellous bone volume and trabecular number and decreased trabecular separation. Changes in trabecular width were variable, suggesting that the increase in trabecular number was due to the observed intratrabecular tunneling. Cortical width remained unchanged; however, hPTH 1-34 treatment increased cortical porosity. Cancellous bone remodeling was also stimulated, inducing significant changes in osteoid, mineralizing surface, and bone formation rate. Similar changes were seen in endocortical and intracortical remodeling. BMD Z-scores were unchanged at the spine and femoral neck. Total hip Z-scores increased; however, total body BMD Z-scores decreased during the first 6 months of treatment and then stabilized, remaining significantly decreased compared to baseline. Radial Z-scores also decreased with treatment; this was most pronounced in the growing adolescent. Daily hPTH 1-34 therapy for hypoparathyroidism stimulated bone turnover, increased bone volume, and altered bone structure in the iliac crest. These findings suggest that treatment with hPTH 1-34 in hypoparathyroid adults and adolescents has varying effects in the different skeletal compartments, leading to an increase in trabecular bone and an apparent trabecularization of cortical bone.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492501      PMCID: PMC3399961          DOI: 10.1002/jbmr.1627

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  30 in total

1.  A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children: the university of Saskatchewan bone mineral accrual study.

Authors:  D A Bailey; H A McKay; R L Mirwald; P R Crocker; R A Faulkner
Journal:  J Bone Miner Res       Date:  1999-10       Impact factor: 6.741

2.  Rapid growth produces transient cortical weakness: a risk factor for metaphyseal fractures during puberty.

Authors:  Qingju Wang; Xiao-Fang Wang; Sandra Iuliano-Burns; Ali Ghasem-Zadeh; Roger Zebaze; Ego Seeman
Journal:  J Bone Miner Res       Date:  2010-07       Impact factor: 6.741

3.  Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.

Authors:  Kirsti Uusi-Rasi; Lisa M Semanick; Jose R Zanchetta; Cesar E Bogado; Erik F Eriksen; Masahiko Sato; Thomas J Beck
Journal:  Bone       Date:  2005-06       Impact factor: 4.398

4.  Effects of daily treatment with parathyroid hormone 1-84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys.

Authors:  J Fox; M A Miller; M K Newman; R R Recker; C H Turner; S Y Smith
Journal:  Bone       Date:  2007-05-13       Impact factor: 4.398

5.  Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.

Authors:  R R Recker; S P Bare; S Y Smith; A Varela; M A Miller; S A Morris; J Fox
Journal:  Bone       Date:  2008-10-17       Impact factor: 4.398

6.  Therapy of hypoparathyroidism with intact parathyroid hormone.

Authors:  M R Rubin; J Sliney; D J McMahon; S J Silverberg; J P Bilezikian
Journal:  Osteoporos Int       Date:  2010-01-22       Impact factor: 4.507

7.  Dynamic and structural properties of the skeleton in hypoparathyroidism.

Authors:  Mishaela R Rubin; David W Dempster; Hua Zhou; Elizabeth Shane; Thomas Nickolas; James Sliney; Shonni J Silverberg; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

8.  Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism.

Authors:  Karen K Winer; Ninet Sinaii; Donna Peterson; Bruno Sainz; Gordon B Cutler
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

9.  Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.

Authors:  Benjamin Z Leder; Robert M Neer; Jason J Wyland; Hang W Lee; Sherri-Ann M Burnett-Bowie; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2009-05-12       Impact factor: 5.958

10.  PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation.

Authors:  Todd A Theman; Michael T Collins; David W Dempster; Hua Zhou; James C Reynolds; Jaime S Brahim; Paul Roschger; Klaus Klaushofer; Karen K Winer
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741

View more
  27 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

2.  Parathyroid hormone therapy for hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John P Bilezikian
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2014-09-10       Impact factor: 4.690

3.  Recurrent kidney stones in a family with a mitochondrial disorder due to the m.3243A>G mutation.

Authors:  M Bargagli; G Primiano; A Primiano; J Gervasoni; A Naticchia; S Servidei; G Gambaro; P M Ferraro
Journal:  Urolithiasis       Date:  2018-11-07       Impact factor: 3.436

Review 4.  Skeletal changes through the lifespan--from growth to senescence.

Authors:  Joshua N Farr; Sundeep Khosla
Journal:  Nat Rev Endocrinol       Date:  2015-06-02       Impact factor: 43.330

Review 5.  Use of parathyroid hormone in hypoparathyroidism.

Authors:  N E Cusano; M R Rubin; D Irani; J Sliney; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2013-12       Impact factor: 4.256

Review 6.  Risk of vertebral fractures in hypoparathyroidism.

Authors:  Anna Maria Formenti; Francesco Tecilazich; Raffaele Giubbini; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

Review 7.  Bone imaging in hypoparathyroidism.

Authors:  B C Silva; M R Rubin; N E Cusano; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-08-30       Impact factor: 4.507

Review 8.  Causes, mechanisms and management of paediatric osteoporosis.

Authors:  Outi Mäkitie
Journal:  Nat Rev Rheumatol       Date:  2013-04-16       Impact factor: 20.543

9.  The effect of PTH(1-84) on quality of life in hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Dinaz Irani; Amanda Tulley; James Sliney; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2013-04-17       Impact factor: 5.958

10.  Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1-84) Therapy in Hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John M Williams; Sanchita Agarwal; Gaia Tabacco; Donovan Tay; Rukshana Majeed; Beatriz Omeragic; John P Bilezikian
Journal:  J Bone Miner Res       Date:  2020-03-26       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.